vs

Side-by-side financial comparison of Fulgent Genetics, Inc. (FLGT) and IMAX CORP (IMAX). Click either name above to swap in a different company.

IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $71.1M, roughly 1.8× Fulgent Genetics, Inc.). On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs -3.2%). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 0.1%).

Fulgent Genetics, Inc. is a molecular diagnostics technology firm that develops and offers genetic testing services including carrier screening, oncology testing, infectious disease detection, and hereditary condition analysis, serving clinical providers, pharma firms, research institutions and public health groups primarily in North America.

IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.

FLGT vs IMAX — Head-to-Head

Bigger by revenue
IMAX
IMAX
1.8× larger
IMAX
$125.2M
$71.1M
FLGT
Growing faster (revenue YoY)
IMAX
IMAX
+38.3% gap
IMAX
35.1%
-3.2%
FLGT
Faster 2-yr revenue CAGR
IMAX
IMAX
Annualised
IMAX
25.8%
0.1%
FLGT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FLGT
FLGT
IMAX
IMAX
Revenue
$71.1M
$125.2M
Net Profit
$637.0K
Gross Margin
30.2%
57.6%
Operating Margin
21.1%
19.3%
Net Margin
0.5%
Revenue YoY
-3.2%
35.1%
Net Profit YoY
-88.0%
EPS (diluted)
$0.04
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FLGT
FLGT
IMAX
IMAX
Q1 26
$71.1M
Q4 25
$83.3M
$125.2M
Q3 25
$84.1M
$106.7M
Q2 25
$81.8M
$91.7M
Q1 25
$73.5M
$86.7M
Q4 24
$76.2M
$92.7M
Q3 24
$71.7M
$91.5M
Q2 24
$71.0M
$89.0M
Net Profit
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
$-23.4M
$637.0K
Q3 25
$-6.6M
$20.7M
Q2 25
$-19.0M
$11.3M
Q1 25
$-11.5M
$2.3M
Q4 24
$-5.9M
$5.3M
Q3 24
$-14.6M
$13.9M
Q2 24
$-8.7M
$3.6M
Gross Margin
FLGT
FLGT
IMAX
IMAX
Q1 26
30.2%
Q4 25
39.1%
57.6%
Q3 25
42.2%
63.1%
Q2 25
42.1%
58.5%
Q1 25
38.6%
61.4%
Q4 24
41.8%
52.2%
Q3 24
37.3%
55.8%
Q2 24
37.3%
49.4%
Operating Margin
FLGT
FLGT
IMAX
IMAX
Q1 26
21.1%
Q4 25
-43.5%
19.3%
Q3 25
-18.3%
27.2%
Q2 25
-24.1%
15.6%
Q1 25
-26.9%
19.3%
Q4 24
-21.2%
10.3%
Q3 24
-23.8%
21.2%
Q2 24
-26.6%
3.2%
Net Margin
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
-28.1%
0.5%
Q3 25
-7.9%
19.4%
Q2 25
-23.2%
12.3%
Q1 25
-15.7%
2.7%
Q4 24
-7.7%
5.7%
Q3 24
-20.4%
15.2%
Q2 24
-12.3%
4.0%
EPS (diluted)
FLGT
FLGT
IMAX
IMAX
Q1 26
$0.04
Q4 25
$0.02
Q3 25
$0.37
Q2 25
$0.20
Q1 25
$0.04
Q4 24
$0.09
Q3 24
$0.26
Q2 24
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FLGT
FLGT
IMAX
IMAX
Cash + ST InvestmentsLiquidity on hand
$23.4M
$151.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$337.9M
Total Assets
$1.2B
$894.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FLGT
FLGT
IMAX
IMAX
Q1 26
$23.4M
Q4 25
$50.2M
$151.2M
Q3 25
$117.6M
$143.1M
Q2 25
$87.9M
$109.3M
Q1 25
$67.3M
$97.1M
Q4 24
$55.1M
$100.6M
Q3 24
$58.0M
$104.5M
Q2 24
$65.1M
$91.6M
Stockholders' Equity
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
$1.1B
$337.9M
Q3 25
$1.1B
$349.5M
Q2 25
$1.1B
$320.4M
Q1 25
$1.1B
$299.5M
Q4 24
$1.1B
$299.5M
Q3 24
$1.1B
$289.4M
Q2 24
$1.1B
$267.2M
Total Assets
FLGT
FLGT
IMAX
IMAX
Q1 26
$1.2B
Q4 25
$1.2B
$894.0M
Q3 25
$1.2B
$889.6M
Q2 25
$1.2B
$868.6M
Q1 25
$1.2B
$848.3M
Q4 24
$1.2B
$830.4M
Q3 24
$1.2B
$847.6M
Q2 24
$1.2B
$827.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FLGT
FLGT
IMAX
IMAX
Operating Cash FlowLast quarter
$29.4M
Free Cash FlowOCF − Capex
$28.0M
FCF MarginFCF / Revenue
22.3%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
46.11×
TTM Free Cash FlowTrailing 4 quarters
$118.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
$-78.1M
$29.4M
Q3 25
$11.1M
$67.5M
Q2 25
$-30.2M
$23.2M
Q1 25
$-4.4M
$7.0M
Q4 24
$25.0M
$11.5M
Q3 24
$-15.5M
$35.3M
Q2 24
$4.3M
$35.0M
Free Cash Flow
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
$-83.1M
$28.0M
Q3 25
$5.1M
$64.8M
Q2 25
$-37.0M
$20.9M
Q1 25
$-9.1M
$5.3M
Q4 24
$21.2M
$6.9M
Q3 24
$-35.0M
$34.2M
Q2 24
$-8.7M
$33.5M
FCF Margin
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
-99.7%
22.3%
Q3 25
6.0%
60.7%
Q2 25
-45.2%
22.8%
Q1 25
-12.5%
6.1%
Q4 24
27.9%
7.4%
Q3 24
-48.8%
37.3%
Q2 24
-12.2%
37.6%
Capex Intensity
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
6.0%
1.1%
Q3 25
7.2%
2.6%
Q2 25
8.3%
2.6%
Q1 25
6.4%
1.9%
Q4 24
5.0%
5.0%
Q3 24
27.2%
1.2%
Q2 24
18.2%
1.8%
Cash Conversion
FLGT
FLGT
IMAX
IMAX
Q1 26
Q4 25
46.11×
Q3 25
3.27×
Q2 25
2.06×
Q1 25
2.99×
Q4 24
2.16×
Q3 24
2.54×
Q2 24
9.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FLGT
FLGT

Segment breakdown not available.

IMAX
IMAX

Technology Sales$46.6M37%
Image Enhancement And Maintenance Services$38.1M30%
Joint Revenue Sharing Arrangement$20.4M16%
Maintenance$16.3M13%
Finance Income$2.8M2%
Other Content Solutions$1.6M1%

Related Comparisons